vs
Orthofix Medical Inc.（OFIX）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是Orthofix Medical Inc.的1.9倍（$411.1M vs $219.9M），UiPath, Inc.净利率更高（48.4% vs -1.0%，领先49.4%），UiPath, Inc.同比增速更快（15.9% vs 2.0%），UiPath, Inc.自由现金流更多（$25.1M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 0.7%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
OFIX vs PATH — 直观对比
营收规模更大
PATH
是对方的1.9倍
$219.9M
营收增速更快
PATH
高出13.9%
2.0%
净利率更高
PATH
高出49.4%
-1.0%
自由现金流更多
PATH
多$8.3M
$16.8M
两年增速更快
OFIX
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $411.1M |
| 净利润 | $-2.2M | $198.8M |
| 毛利率 | 71.1% | 83.3% |
| 营业利润率 | 0.2% | 3.2% |
| 净利率 | -1.0% | 48.4% |
| 营收同比 | 2.0% | 15.9% |
| 净利润同比 | 92.4% | 1966.2% |
| 每股收益（稀释后） | $-0.05 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPATH
| Q4 25 | $219.9M | $411.1M | ||
| Q3 25 | $205.6M | $361.7M | ||
| Q2 25 | $203.1M | $356.6M | ||
| Q1 25 | $193.6M | $423.6M | ||
| Q4 24 | $215.7M | $354.7M | ||
| Q3 24 | $196.6M | $316.3M | ||
| Q2 24 | $198.6M | $335.1M | ||
| Q1 24 | $188.6M | $405.3M |
净利润OFIXPATH
| Q4 25 | $-2.2M | $198.8M | ||
| Q3 25 | $-22.8M | $1.6M | ||
| Q2 25 | $-14.1M | $-22.6M | ||
| Q1 25 | $-53.1M | $51.8M | ||
| Q4 24 | $-29.1M | $-10.7M | ||
| Q3 24 | $-27.4M | $-86.1M | ||
| Q2 24 | $-33.4M | $-28.7M | ||
| Q1 24 | $-36.0M | $33.9M |
毛利率OFIXPATH
| Q4 25 | 71.1% | 83.3% | ||
| Q3 25 | 72.2% | 82.2% | ||
| Q2 25 | 68.7% | 82.1% | ||
| Q1 25 | 62.8% | 84.8% | ||
| Q4 24 | 69.0% | 82.0% | ||
| Q3 24 | 68.7% | 80.0% | ||
| Q2 24 | 67.8% | 83.5% | ||
| Q1 24 | 67.5% | 86.8% |
营业利润率OFIXPATH
| Q4 25 | 0.2% | 3.2% | ||
| Q3 25 | -8.3% | -5.6% | ||
| Q2 25 | -7.9% | -4.6% | ||
| Q1 25 | -25.2% | 7.9% | ||
| Q4 24 | -5.3% | -12.2% | ||
| Q3 24 | -9.6% | -32.7% | ||
| Q2 24 | -12.5% | -14.8% | ||
| Q1 24 | -15.6% | 3.7% |
净利率OFIXPATH
| Q4 25 | -1.0% | 48.4% | ||
| Q3 25 | -11.1% | 0.4% | ||
| Q2 25 | -6.9% | -6.3% | ||
| Q1 25 | -27.4% | 12.2% | ||
| Q4 24 | -13.5% | -3.0% | ||
| Q3 24 | -13.9% | -27.2% | ||
| Q2 24 | -16.8% | -8.6% | ||
| Q1 24 | -19.1% | 8.4% |
每股收益（稀释后）OFIXPATH
| Q4 25 | $-0.05 | $0.37 | ||
| Q3 25 | $-0.57 | $0.00 | ||
| Q2 25 | $-0.36 | $-0.04 | ||
| Q1 25 | $-1.35 | $0.09 | ||
| Q4 24 | $-0.76 | $-0.02 | ||
| Q3 24 | $-0.71 | $-0.15 | ||
| Q2 24 | $-0.88 | $-0.05 | ||
| Q1 24 | $-0.95 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $1.9B |
| 总资产 | $850.6M | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXPATH
| Q4 25 | $82.0M | $1.4B | ||
| Q3 25 | $62.9M | $1.4B | ||
| Q2 25 | $65.6M | $1.6B | ||
| Q1 25 | $58.0M | $1.6B | ||
| Q4 24 | $83.2M | $1.6B | ||
| Q3 24 | $30.1M | $1.7B | ||
| Q2 24 | $26.4M | $1.9B | ||
| Q1 24 | $27.0M | $1.9B |
总债务OFIXPATH
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXPATH
| Q4 25 | $450.0M | $1.9B | ||
| Q3 25 | $442.5M | $1.7B | ||
| Q2 25 | $458.3M | $1.7B | ||
| Q1 25 | $458.3M | $1.8B | ||
| Q4 24 | $503.1M | $1.7B | ||
| Q3 24 | $525.9M | $1.8B | ||
| Q2 24 | $546.0M | $2.0B | ||
| Q1 24 | $570.3M | $2.0B |
总资产OFIXPATH
| Q4 25 | $850.6M | $2.9B | ||
| Q3 25 | $832.6M | $2.6B | ||
| Q2 25 | $837.2M | $2.6B | ||
| Q1 25 | $823.1M | $2.9B | ||
| Q4 24 | $893.3M | $2.7B | ||
| Q3 24 | $867.9M | $2.7B | ||
| Q2 24 | $882.0M | $2.8B | ||
| Q1 24 | $906.0M | $3.0B |
负债/权益比OFIXPATH
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $25.1M |
| 自由现金流率自由现金流/营收 | 7.6% | 6.1% |
| 资本支出强度资本支出/营收 | 4.9% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 0.14× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXPATH
| Q4 25 | $27.7M | $28.3M | ||
| Q3 25 | $12.4M | $41.6M | ||
| Q2 25 | $11.6M | $119.0M | ||
| Q1 25 | $-18.4M | $146.1M | ||
| Q4 24 | $23.7M | $28.1M | ||
| Q3 24 | $11.7M | $46.4M | ||
| Q2 24 | $9.0M | $100.0M | ||
| Q1 24 | $-18.6M | $145.6M |
自由现金流OFIXPATH
| Q4 25 | $16.8M | $25.1M | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.5M | $106.2M | ||
| Q1 25 | $-25.1M | $138.7M | ||
| Q4 24 | $15.2M | $23.2M | ||
| Q3 24 | $6.3M | $45.0M | ||
| Q2 24 | $-360.0K | $98.8M | ||
| Q1 24 | $-29.1M | $141.8M |
自由现金流率OFIXPATH
| Q4 25 | 7.6% | 6.1% | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.2% | 29.8% | ||
| Q1 25 | -13.0% | 32.7% | ||
| Q4 24 | 7.0% | 6.5% | ||
| Q3 24 | 3.2% | 14.2% | ||
| Q2 24 | -0.2% | 29.5% | ||
| Q1 24 | -15.4% | 35.0% |
资本支出强度OFIXPATH
| Q4 25 | 4.9% | 0.8% | ||
| Q3 25 | 4.8% | 0.0% | ||
| Q2 25 | 3.5% | 3.6% | ||
| Q1 25 | 3.5% | 1.7% | ||
| Q4 24 | 4.0% | 1.4% | ||
| Q3 24 | 2.7% | 0.4% | ||
| Q2 24 | 4.7% | 0.4% | ||
| Q1 24 | 5.6% | 0.9% |
现金转化率OFIXPATH
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 26.25× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
